Photocure Studies Show Blue Light Cystoscopy Cuts Recurrence, Narrows Cost Gap in Bladder Cancer

Event summary

  • Two Photocure-supported studies presented at AUA 2026 demonstrate Blue Light Cystoscopy (BLC) improves detection of high-risk bladder cancer and reduces recurrence rates.
  • BLC associated with 8.5% CIS detection vs. 3.4% with white light, and 4.6% cystectomy rate vs. 2.3% in real-world U.S. claims cohort.
  • BRAVO study shows BLC costs approach neutrality at 5 years due to lower recurrence rates, despite higher initial outpatient expenses.
  • BLC use linked to 61% BCG therapy adoption vs. 43% with white light in equal-access VA healthcare setting.

The big picture

Photocure's data reinforces the strategic shift toward precision diagnostics in bladder cancer management, where early detection and risk stratification can significantly reduce treatment costs and improve outcomes. The findings position BLC as a potential standard of care for high-risk NMIBC patients, addressing both clinical and economic challenges in a disease with notoriously high recurrence rates and lifetime treatment costs.

What we're watching

Adoption Dynamics
Whether BLC can achieve broader clinical adoption despite higher initial costs and outpatient expenses.
Cost Neutrality
The pace at which BLC's cost advantages from recurrence reduction will drive payer and provider acceptance.
Therapeutic Impact
How BLC's ability to guide risk-appropriate management will affect long-term patient outcomes in high-risk NMIBC cases.